55
68) Abdullah AN, Keczkes K. Cutaneous and ocular side-effects of PUVA photochemotherapy: a 10-year follow-up study. Clin Exp Dermatol 1989; 14: 421-4.
69) Chuang TY, Heinrich LA, Schultz MD et al. PUVA and skin cancer. A historical cohort study on 492 patients. J Am Acad Dermatol 1992; 26: 173-7.
70) Wang SQ, Setlow R, Berwick M, Polsky D, Marghoob AA, Kopf AW et al. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001; 44: 837-46.
71) Stern RS. PUVA follow-up study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-61.
72) Weinstock MA, Coulter S, Bates J, Bogaars HA, Larson PL, Burmer GC. Human papillomavirus and widespread cutaneous carcinoma after PUVA photochemotherapy. Arch Dermatol 1995; 131: 701-4.
73) Bruynzeel I, Bergman W, Hartevelt HM, Kenter CC, Van de Velde EA, Schothorst AA et al. ‘High single-dose’ European PUVA regimen also causes an excess of nonmelanoma skin cancer. Br J Dermatol 1991; 124: 49-55.
74) Shephard SE, Panizzon RG. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy. Dermatology 1999; 199: 106-12.
75) Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49: 506-9.
76) Wakita D, Chamoto K, Ohkuri T, Narita Y, Ashino S, Sumida K, Nishikawa H, Shiku H, Togashi Y, Kitamura H, Nishimura T. IFN-gamma-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis 2009; 30: 1408-15.
77) Beissert S, Rühlemann D, Mohammad T et al. IL-12 prevents the inhibitory effects of cis-urocanic acid on tumor antigen presentation by Langerhans cells: implications for photocarcinogenesis. J Immunol 2001; 167: 6232-8.
78) Seidl H, Kreimer-Erlacher H, Bck B, Soyer HP, Höfler G, Kerl H et al. Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A-treated patients with psoriasis. J Invest Dermatol 2001; 117: 365-70.
79) Jackson S, Storey A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 2000; 19: 592-8.
80) McKenna KE. Iatrogenic skin cancer: induction by psoralen/ultraviolet A and immunosuppression of organ transplant recipients. Iatrogenic skin cancer: induction by



64. SAYFADAKI ANAHTAR KELIMELER

acad
oral
with
puva
stern
melanoma


64. SAYFA ICERIGI

55
68) Abdullah AN, Keczkes K. Cutaneous and ocular side-effects of PUVA photochemotherapy: a 10-year follow-up study. Clin Exp Dermatol 1989; 14: 421-4.
69) Chuang TY, Heinrich LA, Schultz MD et al. PUVA and skin cancer. A historical cohort study on 492 patients. J Am Acad Dermatol 1992; 26: 173-7.
70) Wang SQ, Setlow R, Berwick M, Polsky D, Marghoob AA, Kopf AW et al. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001; 44: 837-46.
71) Stern RS. PUVA follow-up study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-61.
72) Weinstock MA, Coulter S, Bates J, Bogaars HA, Larson PL, Burmer GC. Human papillomavirus and widespread cutaneous carcinoma after PUVA photochemotherapy. Arch Dermatol 1995; 131: 701-4.
73) Bruynzeel I, Bergman W, Hartevelt HM, Kenter CC, Van de Velde EA, Schothorst AA et al. ‘High single-dose’ European PUVA regimen also causes an excess of nonmelanoma skin cancer. Br J Dermatol 1991; 124: 49-55.
74) Shephard SE, Panizzon RG. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy. Dermatology 1999; 199: 106-12.
75) Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49: 506-9.
76) Wakita D, Chamoto K, Ohkuri T, Narita Y, Ashino S, Sumida K, Nishikawa H, Shiku H, Togashi Y, Kitamura H, Nishimura T. IFN-gamma-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis 2009; 30: 1408-15.
77) Beissert S, Rühlemann D, Mohammad T et al. IL-12 prevents the inhibitory effects of cis-urocanic acid on tumor antigen presentation by Langerhans cells: implications for photocarcinogenesis. J Immunol 2001; 167: 6232-8.
78) Seidl H, Kreimer-Erlacher H, Bck B, Soyer HP, Höfler G, Kerl H et al. Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A-treated patients with psoriasis. J Invest Dermatol 2001; 117: 365-70.
79) Jackson S, Storey A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 2000; 19: 592-8.
80) McKenna KE. Iatrogenic skin cancer: induction by psoralen/ultraviolet A and immunosuppression of organ transplant recipients. Iatrogenic skin cancer: induction by

İlgili Kaynaklar

single.php